In This Section      
Print This Page

Jerry Spivak, M.D.

Professor of Medicine and Oncology
Director, Center for the Chronic Myeloproliferative Disorders

Contact Information:
Appointments: 410-955-3142 
Administrative Office: 410-614-0167

Clinical and Academic Interests:
The chronic myeloproliferative disorders,
polycythemia vera,
idiopathic myelofibrosis,
essential thrombocytosis, hypereosinophilia,
stocytosis; erythrocytosis and erythropoietin physiology.

Dr. Jerry L. Spivak



Research Interests:
Dr. Spivak’s research interests are focused on the chronic myeloproliferative
disorders with particular emphasis on the molecular basis of these disorders
and the means for distinguishing them both diagnostically and with respect
to therapeutic intervention. Using techniques to analyze gene expression in
polycythemia vera stem cells, he has found that polycythemia vera patients
can be distinguished from patients with erythrocytosis and also divided in to
two groups, those with an aggressive disease and those with a more indolent
illness. Dr. Spivak and his colleagues are also studying the role of specific
molecular markers identified at Johns Hopkins and elsewhere with respect
to the pathogenesis of polycythemia vera as well as its diagnosis.



Princeton University, A.B. Magna Cum Laude


Cornell University Medical College, M.D.


Internship and Residency, Osler Medical Service, Johns Hopkins Hospital


Clinical Associate, National Cancer Institute, N.I.H., Bethesda, MD


Senior Assistant Resident, New York Hospital, NYC,New York


Fellow, Hematology Division, Johns Hopkins University School of Medicine


Chief Medical Resident, Johns Hopkins University School of Medicine





Assistant Professor of Medicine, Johns Hopkins University School of Medicine


Investigator, The Howard Hughes Medical Institute


Associate Professor of Medicine, Johns Hopkins University School of Medicine


Associate Professor of Oncology, Johns Hopkins University School of Medicine


Director, Division of Hematology, Johns Hopkins University School of Medicine


Professor of Medicine, Johns Hopkins University School of Medicine


 Professor of Oncology, Johns Hopkins University School of Medicine

Selected Publications:

Moliterno A R, Hankins WD and Spivak, JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N.Engl. J. Med. 338: 572-1998.

Moliterno A R and Spivak JL. Post-translational processing of the thrombopoietin receptor is impaired in polycythemia vera.  Blood. 94:2555, 1999.

Spivak, JL.  The optimal management of polycythemia vera.Br J Haematol. 116:243, 2002.

Streiff, MB, Smith, B and Spivak, JL.  The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group.  Blood. 99:1144, 2002.

Spivak, JL, Polycythemia Vera: myths, mechanisms and management. Blood. 100:4272, 2002.

Spivak JL. Polycythemia Vera and the Emperor’s New Clothes. Haematologica 88:1, 2. 

Spivak, JL., The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
Semin Hematol. 2004 Apr;41(2 Suppl 3):1-5.

Spivak, JL., Daily aspirin- Only half the answer. N Engl J Med 350: 99, 2004. 

Malins, DC, Anderson, KM, Polissar, NL, Ostrander, GL and Spivak, JL, Models of Granulocyte DNA Structure are Highly Predictive of the Myelodysplastic Syndrome. PNAS  101:5008, 2004. 

Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis. PNAS 101:11444, 2004.

Spivak, JL. The Anemia of Cancer: Death by a Thousand Cuts. Nature Reviews Cancer. In press 2005.

Spivak, JL  Anemia in the elderly: Time for new blood in old vessels? Arch Int Med:165:2187, 2005.

Tefferi, A and Spivak, JL. Polycythemia Vera: scientific advances and current practice Semin. Hematol. 42:206,  2005. 

Spivak, JL Prediction of Chemotherapy-induced anaemia: is knowledge really power? Lancet Oncology 6:822, 2005.

Spivak, JL. Polycythemia Vera; Idiopathic Myelofibrosis; Essential Thrombocytosis in Harrison’s Handbook of Medical  Oncology, 2007.

Spivak, JL. Lenolidamide and the 3 Ms: deja vu all over again? Blood 108, 1118, 2006.

Spivak, JL. Animal models of the MPD: lack of the clones. Blood 108:1427, 2006.

Moliterno, AR, Williams, DM, Rogers, O, and Spivak, JL. Molecular mimicry in the myeloproliferative disorders: reciprocity between quantitative JAK2 V617F expression and Mpl expression. Blood 108: 3913, 2006,

oliterno, AR and Spivak, JL. Polcythemia vera: clinical aspects. in Myeloproliferative Disorders Melo JV and Goldman JM editors. Springer-Verlag, , 2007.